A phase III registration study of Nelotanserin in Lewy Body Dementia (LBD) patients.

Trial Profile

A phase III registration study of Nelotanserin in Lewy Body Dementia (LBD) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 New trial record
    • 13 Feb 2017 According to Axovant Sciences media release, company plans to begin this study in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top